Bexion Pharmaceuticals to Present Poster at SITC 39th Annual Meeting

COVINGTON, Ky., Nov. 5, 2024 – Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in biologic therapies for solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), has announced their participation in the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. This event will occur from November 6 to 11, 2024, in Houston, TX. A notable feature of Bexion's involvement is their poster presentation on November 8, 2024.

The poster, titled "BXQ-350: A novel approach to rebalancing the tumor's immune response," will be presented by Gilles Tapolsky, PhD, Vice President of Pharmacology at Bexion Pharmaceuticals. The abstract for this presentation, numbered 1331, highlights the innovative methods employed by BXQ-350 in addressing tumor immune responses. Attendees can access all posters starting November 7, 2024, via the virtual meeting platform.

The Society for Immunotherapy of Cancer (SITC) stands out as the premier member-driven organization dedicated to improving cancer patient outcomes through advancements in cancer immunotherapy science and application. With a membership exceeding 4,500 professionals across 35 medical specialties in 63 countries, SITC emphasizes high-quality scientific meetings, educational outreach, and critical initiatives within the field. The organization also collaborates with both domestic and international partners, including government and regulatory bodies, associations, and patient advocacy groups, fostering a comprehensive community focused on cancer immunology and immunotherapy.

BXQ-350, Bexion's leading drug candidate, is a pioneering biologic therapy combining the sphingolipid activator protein, Saposin C, with a phospholipid. This combination has shown promise in various Phase 1 clinical trials involving both adults and children, demonstrating a strong safety profile and notable activity as a single agent across multiple solid tumor types. Beyond its potential in treating solid tumors, clinical and non-clinical data suggest that BXQ-350 could be effective in managing chemotherapy-induced peripheral neuropathy, a significant unmet medical need for patients undergoing treatment with oxaliplatin and other chemotherapy agents.

Bexion Pharmaceuticals, headquartered in Covington, Ky., is committed to developing innovative biologic treatments for solid tumors and CIPN, with an eye towards expanding their portfolio to encompass other cancer types and broader neuropathic pain conditions. Their research spans multiple solid tumor categories, including colorectal cancer, high-grade gliomas, and pediatric brain tumors. Currently, Bexion is enrolling patients for the open-label portion of its Phase 1b/2 study, which evaluates the combination of BXQ-350 with standard treatment in newly diagnosed patients with metastatic colorectal cancer (mCRC). They have also completed patient enrollment for a proof-of-concept trial targeting the treatment of CIPN.

Bexion Pharmaceuticals' engagement at the SITC Annual Meeting underscores their commitment to advancing cancer immunotherapy and addressing critical areas of unmet medical need. Through their innovative research and collaborations, Bexion continues to contribute significantly to the field of cancer treatment, offering hope for improved patient outcomes and new therapeutic options.